Good concordance (92%) for IDH1 mutation identification between tumour tissue and ctDNA was also reported in the ClarIDHy phase III trial, exploring the role of ivosidenib in IDH1-mutant iCCA [40]. The gene discussed is IDH1; the disease is neoplasm.